Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · May 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called IgPro20 to see if it can help prevent infections in people who have multiple myeloma (a type of blood cancer) and a condition called hypogammaglobulinemia, which means they have low levels of certain antibodies that help fight infections. The trial is specifically looking at patients who are receiving treatment with bispecific monoclonal antibodies (a type of targeted therapy). Researchers hope that by giving IgPro20, they can reduce the risk of infections that these patients may face during their treatment.

To participate in this study, individuals must be diagnosed with relapsed or refractory multiple myeloma and currently receiving a bispecific antibody treatment. They should be at least 18 years old and generally in good health, with a life expectancy of more than 12 months. However, certain health issues, such as recent major infections or specific blood conditions, may prevent someone from joining the trial. Participants will receive the study medication and will be monitored for its effects on their health and infection rates. This trial is currently recruiting, and all genders are welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of RRMM receiving a commercially available bispecific antibody
• • Received at least 1 but no more than 4 cycles of BsAb
• • Received 2 or more lines of therapy for MM IgG ≤ 4 g/L excluding paraprotein. For IgG Kappa MM, hypogammaglobulinemia will be determined by subtracting the M spike from IgG
• • Males or females greater than or equal to 18 years old at the time of consent
• • ECOG ≤ 3
• • Life expectancy \> 12 months
• Exclusion Criteria:
• • HSCT within 3 months before enrollment
• • Planned CAR-T therapy in the next 6 months
• • \>1 major (deep-seated) infection within the preceding 3 months
• • HIV infection, Active HCV, or Active HBV infection
• • Pregnancy
• • Neutrophils \< 500 x 10\^9 per mL, Platelets \< 30 x 10\^9 per mL
• • History of cancer other than MM in the last 3 years requiring active chemotherapy or radiation
• • Known reaction/allergy to IgG products
• • Intracranial hemorrhage or embolic CVA in the last 6 months
• • Hyperproteinemia
• • Protein-losing enteropathy
• • Creatinine Cl \<30 ml/min
• • Documented progression on BsAb
• • Known history of Hyperprolinemia
• • On current or previous IVIG (in the last 3 months)